Summary of minutes of EUCAST Steering Committee Meeting  
Brussels, Belgium, 4-5 February 2013

**Attending**
- Dr Petra Apfalter  
  PA EUCAST  
  Austria
- Dr Derek F.J. Brown  
  DB Scientific Secretary  
  United Kingdom
- Dr Rafael Cantón  
  RC Chairperson  
  Spain
- Dr Christian Giske  
  CG SRGA  
  Sweden
- Dr Robin Howe  
  RH BSAC  
  United Kingdom
- Prof Gunnar Kahlmeter  
  GK Clinical Data Co-ordinator  
  Sweden
- Prof Luis Martinez-Martínez  
  LM EUCAST  
  Spain
- Prof Johan W. Mouton  
  JM CRG  
  The Netherlands
- Dr Robert Skov  
  RS EUCAST  
  Denmark
- Prof Claude-James Soussy  
  CS CA-SFM  
  France
- Dr Martin Steinbak  
  MS NWGA  
  Norway

**Apologies**
- Prof Alasdair P. MacGowan  
  AM BSAC  
  United Kingdom

**Present for item 20-22**
- Prof Emmanuelle Cambau  
  EC ESCMID Study Group on Mycobacterial infections, Paris

**Present on 5 February 2013**
- Dr Radu Botgros  
  RB EMA  
  United Kingdom

**Present for item 21**
- Company representatives

---

1. **Chairman’s welcome**

2. **Minutes of meeting of 12-13 November 2012**  
   With minor corrections the minutes were accepted as a correct record.

3. **Matters arising from minutes of 24-25 September 2012 (items not covered by agenda)**  
   MIC distributions for *N. gonorrhoeae* are being sought.

4. **New agents**  
   Ceftaroline: A rationale document for EUCAST breakpoints is being prepared.
   - New antimycobacterial agent: Breakpoints have been proposed.
   - New cephalosporin agent: Breakpoints have been proposed.
   - Doripenem: Proposals for revision of breakpoints were discussed.
   - The current status of several other agents in various stages of development was discussed.

5. **EUCAST rationale documents**  
   Fosfomycin and fosfomycin trometamol rationale documents will be released following minor amendments.

6. **Subcommittees**  
   Antifungal susceptibility testing: Breakpoints for micafungin and revised breakpoints for anidulafungin and fluconazole with *Candida* spp. have been distributed for wide consultation.
   - Detection of resistance mechanisms of clinical and/or epidemiological importance: A draft document is being updated following wide consultation.

7. **Breakpoint tables**  
   Version 3.0 has been released. A draft table of breakpoints for topical agents will be revised following consultation.

8. **Breakpoint issues**  
   A proposal for ciprofloxacin breakpoints of $S \leq 4 \text{ mg/L}$ and $R > 4 \text{ mg/L}$ for enterococci will be released for wide consultation.
The gentamicin breakpoint for staphylococci is being reviewed.

A project is being set up to investigate disk diffusion methods for rapidly growing anaerobes.

Specific disk diffusion criteria will be introduced for cefoxitin with *S. pseudointermedius*.

A disk diffusion test to detect fluoroquinolone resistance in *Salmonella* is being developed.

Data on *Yersinia enterocolitica* will be reviewed.

Detailed practical guidelines are being prepared for detection of dissociated macrolide resistance.

Organisms without EUCAST breakpoints

Breakpoints or guidelines are being developed for *Legionella* spp., *Burkholderia cepacia*, *Actinomyces* spp., *Corynebacterium* spp., *Pseudomonas* spp. other than *P. aeruginosa*, and a range of rarer organisms.

EUCAST methods QC tables version 3.0 were published in December 2012.

Implementation of EUCAST breakpoints Data from a survey of implementation of EUCAST guidelines is being collated. Compliance of manufacturers tables on the website are being updated. EUCAST documents are freely available from the website and can be freely redistributed but not sold to others. Translations of documents to languages other than English by EUCAST NACs may be published on the EUCAST website as long as the NAC agrees to take responsibility for updates.

EUCAST website No additional information.

Publications and presentations Paper explaining ECOFFs, reporting as found for Enterobacteriaceae and the EUCAST disk diffusion method are in preparation.

NACs General Committee representatives will be reminded of the procedure for visiting representatives on Steering Committee. There has been one application, from Germany, for the General Committee seat on the Steering Committee for two years from May 2013.

EUCAST SOPs SOPs on revision of breakpoints (SOP 3.0), EUCAST committees (SOP 4.0) and interaction of Steering Committee with NACs (SOP 5.0) have been released on the website.

ESCMID A EUCAST activities page will be included in the programme for ECCMID Berlin 2013.

EMA EMA guidelines on conflicts of interest in relation to EUCAST were discussed.

CLSI There was discussion of possible guidelines for manufacturers on the PK/PD data and format required for breakpoint setting, so that there is international standardisation.

ECDC List of agents recommended for testing have been sent to ECDC.

Antituberculosis agent Following a presentation from the company and subsequent discussion, proposals for breakpoints were formulated.

Any other business None.

Next meetings

30 April -1 May 2013, Berlin, Germany (immediately following ECCMID).
8-9 July 2013, Copenhagen, Denmark.
25-26 November 2013, Brussels, Belgium.
10-11 February 2014, Munich, Germany.
13-14 May 2014, Barcelona, Spain (immediately following ECCMID).
7-8 July 2014, Stockholm, Sweden (may be switched with Sept 2014).
22-23 September 2014, Copenhagen, Denmark.